Table 3.

Association between race and survival in various cancers^*

	Adjusted for clinical prognostic factors†		Adjusted for clinical prognostic factors, income, and education					Estimated cause-specific survival‡
Disease	HR (95% CI)	P§	% With available SES data	% Income‖ (AA vs other)	% Education‖ (AA vs other)	HR (95% CI)	P§	HR (95% CI)	P§
Premenopausal breast cancer	1.41 (1.10 to 1.82)	.007	72	45 vs 74	41 vs 73	1.43 (1.11 to 1.84)	.006	1.41 (1.09 to 1.84)	.01
Postmenopausal breast cancer	1.49 (1.28 to 1.73)	<.001	68	32 vs 67	26 vs 67	1.48 (1.27 to 1.72)	<.001	1.39 (1.17 to 1.66)	<.001
AML	1.12 (0.97 to 1.30)	.12	44	23 vs 60	27 vs 62	1.10 (0.95 to 1.28)	.20	1.05 (0.83 to 1.33)	.66
Limited-stage SCLC	1.13 (0.90 to 1.42)	.29	21	21 vs 62	7 vs 64	1.13 (0.90 to 1.42)	.28	1.11 (0.77 to 1.60)	.58
Advanced NSCLC	0.91 (0.79 to 1.05)	.20	63	33 vs 64	33 vs 65	0.88 (0.76 to 1.02)	.08	0.89 (0.75 to 1.05)	.17
Multiple myeloma	0.95 (0.85 to 1.06)	.34	29	23 vs 56	24 vs 61	0.94 (0.84 to 1.05)	.25	0.85 (0.70 to 1.03)	.10
Early-stage colon cancer	1.03 (0.73 to 1.46)	.87	31	44 vs 63	44 vs 63	0.98 (0.69 to 1.40)	.92	0.99 (0.67 to 1.45)	.94
Advanced NHL	1.20 (0.97 to 1.50)	.10	64	44 vs 60	33 vs 62	1.17 (0.94 to 1.45)	.17	1.31 (1.00 to 1.71)	.05
Advanced ovarian carcinoma	1.61 (1.18 to 2.18)	.002	73	29 vs 69	34 vs 69	1.65 (1.21 to 2.24)	.002	1.48 (1.03 to 2.11)	.03
Advanced-stage prostate cancer	1.21 (1.08 to 1.37)	.001	71	25 vs 67	21 vs 70	1.19 (1.05 to 1.35)	.008	1.19 (1.05 to 1.35)	.008

^*HR = hazard ratio; CI = confidence interval; SES =  socioeconomic status; AA = African American; AML = acute myelogenous leukemia; NHL = non-Hodgkin lymphoma; SCLC = small cell lung cancer; NSCLC = non–small cell lung cancer.

^†Clinical prognostic factors are listed in Table 1.

^‡Data were estimated on the basis of deaths after documented progression and adjusted for clinical prognostic factors.

^§Wald χ² statistic. All statistical tests were two-sided.

^‖Data are the percentage from high-income areas or from high-education areas.